Mobile

A trial evaluating compatibility and safety of FIAsp and insulin aspart with an external continuous subcutaneous insulin infusion system in adult subjects with type 1 diabetes

Mise à jour : Il y a 4 ans
Référence : U1111-1143-2316

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the compatibility of faster acting insulin aspart (FIAsp) and insulin aspart with the external continuous subcutaneous insulin (CSII) system over a 6-week treatment period.

Critère d'inclusion

  • Diabetes Mellitus, Type 1

Liens